Rectal cancer and Lymphangiosis carcinomatosa


Lymphangiosis carcinomatosa is found among people with Rectal cancer, especially for people who are male, 60+ old.

The study analyzes which people have Lymphangiosis carcinomatosa with Rectal cancer. It is created by eHealthMe based on reports of 9 people who have Rectal cancer from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Apr, 01, 2023

9 people who have Rectal Cancer and Lymphangiosis Carcinomatosa are studied.

What is Rectal cancer?

Rectal cancer (cancer of rectum) is found to be associated with 830 drugs and 466 conditions by eHealthMe.

What is Lymphangiosis carcinomatosa?

Lymphangiosis carcinomatosa (inflammation of the lymph vessels can lead to cancer) is found to be associated with 435 drugs and 246 conditions by eHealthMe.

Number of Lymphangiosis carcinomatosa in Rectal cancer reports submitted per year:

Would you have Lymphangiosis carcinomatosa when you have Rectal cancer?

Gender of people who have Rectal Cancer and experienced Lymphangiosis Carcinomatosa *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Rectal Cancer and experienced Lymphangiosis Carcinomatosa *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 12.5 %
  • 40-49: 0.0 %
  • 50-59: 12.5 %
  • 60+: 75.0 %

Common co-existing conditions for these people *:

  1. Nausea And Vomiting: 1 person, 11.11%
  2. Insomnia (sleeplessness): 1 person, 11.11%
  3. Constipation: 1 person, 11.11%
  4. Cancer Pain: 1 person, 11.11%

Common drugs taken by these people *:

  1. Xeloda: 3 people, 33.33%
  2. Stivarga: 3 people, 33.33%
  3. Avastin: 2 people, 22.22%
  4. Allegra: 2 people, 22.22%
  5. Oxycontin: 1 person, 11.11%
  6. Oxaliplatin: 1 person, 11.11%
  7. Leucovorin Calcium: 1 person, 11.11%
  8. Kytril: 1 person, 11.11%
  9. Fluorouracil: 1 person, 11.11%
  10. Erbitux: 1 person, 11.11%

Common symptoms for these people *:

  1. Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 2 people, 22.22%
  2. Unilateral Hydronephrosis (kidney stone that causes obstruction of the ureter): 2 people, 22.22%
  3. Thrombocytopenia (decrease of platelets in blood): 2 people, 22.22%
  4. Hepatic Function Abnormal: 2 people, 22.22%
  5. Taste - Impaired: 2 people, 22.22%
  6. Cerebral Infarction (less blood supply to brain resulting tissue damage): 2 people, 22.22%
  7. Cough: 2 people, 22.22%
  8. Pneumonia: 2 people, 22.22%
  9. Fever: 2 people, 22.22%
  10. Dizziness Postural: 2 people, 22.22%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Lymphangiosis carcinomatosa?

Check whether Lymphangiosis carcinomatosa is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Lymphangiosis carcinomatosa:

Common drugs associated with Lymphangiosis carcinomatosa:

All the drugs that are associated with Lymphangiosis carcinomatosa:

Common conditions associated with Lymphangiosis carcinomatosa:

All the conditions that are associated with Lymphangiosis carcinomatosa:

How the study uses the data?

The study is based on Lymphangiosis carcinomatosa and Rectal cancer, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: